New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For COV;INTC;MDT;VRTX;BSX;JNJ From The Last 14 Days
Check below for free stories on COV;INTC;MDT;VRTX;BSX;JNJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
July 14, 2014
16:41 EDTINTCIntel initiated with an Outperform at Imperial Capital
Subscribe for More Information
15:24 EDTJNJNotable companies reporting before tomorrow's open
Subscribe for More Information
15:19 EDTJNJ Johnson & Johnson July 105 straddle priced for 1.6% move into Q2
14:27 EDTJNJEarnings Preview: J&J pharmaceutical sales expected to drive Q2
Johnson & Johnson (JNJ) is scheduled to report second quarter earnings before the market open on Tuesday, July 15, with a conference call scheduled for 8:30 am ET. Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. EXPECTATIONS: Analysts are looking for earnings per share of $1.55 on revenue of $18.94B, according to First Call. The consensus range for EPS is $1.45-$1.61 on revenue of $18.55B-$19.30B. LAST QUARTER: Johnson & Johnson reported first quarter EPS of $1.54 against estimates of $1.48 on revenue of $18.1B against estimates of $18B. The drug maker raised its fiscal year EPS view to $5.80-$5.90 against a consensus estimate of $5.83. J&J noted a 3.2% decrease in worldwide consumer sales in Q1 but saw a 10.8% increase in worldwide pharmaceutical sales. Primary contributors to operational sales growth in Q1 pharmaceutical sales were Stelara, Invega, Sustenna/Xeplion, Prezista, Velcade and sales of new products. Pharmaceutical sales results were negatively impacted by loss of exclusivity for Aciphex, a proton pump inhibitor for gastrointestinal disorders and Concerta for the treatment of attention deficit hyperactivity disorder. STREET RESEARCH: On July 14, RBC Capital raised its Q2 estimates for Johnson & Johnson to reflect the firm's outlook for higher pharmaceutical sales by the company. The firm raised its price target on the shares to $110 from $106 and kept an Outperform rating on the stock. PRICE ACTION: Shares of Johnson & Johnson are up approximately 8.5% since its last earnings report, and are trading near flat in afternoon trading.
13:02 EDTINTCIntel technical comments ahead of earnings
Subscribe for More Information
12:24 EDTJNJJohnson & Johnson technical notes before earnings
The company is scheduled to report before market open on July 15th. The shares in the prior three months have risen by more than 8%, anticipating positive news for the current and forthcoming quarters. At the current price of $105.39, the only remaining established resistance on the daily chart is at the life high of $106.74. If the news and guidance is better than expected, a run to $110, or $115 at an extreme, would be possible. If the news fails to meet expectations or guidance is weak, support would be at $102.70, the 50-day moving average. A break below this uptrend support proxy would be a sell signal in many technical trading systems and would break an uptrend in place since early March of this year. On a sliding scale of increasingly weaker news, supports would next be at $99.96, and then at $96.87.
10:00 EDTCOVOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:14 EDTINTCSemiconductor top picks at Topeka
Topeka's anticipates strong unit growth in the smartphone, tablet and wearable end markets and recommends exposure to large/mid cap growth names Intel (INTC), Skyworks (SWKS), Atmel and (ATML), small cap growth name, Rambus (RMBS), and value names Freescale (FSL), Spansion (CODE) and Silicon Motion (SIMO).
09:07 EDTINTCMellanox Q3 guidance likely to be conservative, says Janney Capital
Janney Capital said it expects Mellanox' (MLNX) Q2 revenue to be in-line and for its Q3 guidance to be conservative, as the firm believes the High Performance Computing market has temporarily slowed ahead of Intel's (INTC) release of its Grantley processors. However, the firm thinks that HPC will recover soon and it maintains its Buy rating and $57 fair value estimate on Mellanox.
09:02 EDTBSXBoston Scientific receives CE mark for Ranger drug-coated balloon
Boston Scientific has received CE Mark for the Ranger Paclitaxel-Coated PTA Balloon Catheter. The technology is now in full European market launch. The Balloon provides physicians with an additional option to treat peripheral artery disease, delivering an anti-stenotic drug to diseased vascular tissue while leaving no permanent implant behind.
08:52 EDTINTCIntel volatility increases into Q2 and outlook
Intel July call option implied volatility is at 27, August is at 20, October is at 18; compared to its 26-week average of 19 according to Track Data, suggesting non-directional price movement into the expected release of Q2 on July 15.
08:34 EDTINTCPC market stability could be short-lived, Reuters says
Subscribe for More Information
08:30 EDTJNJJohnson & Johnson should be bought on any weakness, says RBC Capital
Subscribe for More Information
07:12 EDTCOV, MDTCovidien downgraded to Neutral from Overweight at Piper Jaffray
Subscribe for More Information
06:31 EDTCOVCovidien downgraded to Neutral from Overweight at Piper Jaffray
July 12, 2014
18:33 EDTINTCIntel looks to Chinese unbranded makers to boost tablet presence, WSJ says
Subscribe for More Information
July 11, 2014
07:36 EDTJNJJohnson & Johnson Q2 EPS likely to exceed expectations, says Bernstein
Subscribe for More Information
06:06 EDTINTCIntel to unveil 14nm processors, 10nm wafers at IDF in September, DigiTimes says
Subscribe for More Information
July 10, 2014
08:02 EDTVRTXVertex announces retirement of Chief Scientific Officer Mueller
Subscribe for More Information
08:02 EDTMDTCryoLife appoints Pat Mackin as President and CEO effective September 2
Mackin is expected to be appointed to the company's board after his employment begins. Steven Anderson will continue to serve CryoLife (CRY) as its President and Chief Executive Officer until Mackin's employment begins and then continue as its Executive Chairman. Mackin joins CryoLife from Medtronic (MDT), where he most recently served as President of Cardiac Rhythm Disease Management.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use